

## **Richcore Lifesciences launches first-ever enzymatic clean technology, 'Ecosol'**

*Nandita Vijay, Bangalore*

*Saturday, December 03, 2011, 08:00 Hrs [IST]*

Richcore Lifesciences Pvt Ltd, a biotech company dedicated to developing and manufacturing clean technology solutions for the pharmaceutical industry, has commercialized the first-ever enzymatic clean technology, referred to as 'Ecosol'. The patent pending technology treats effluent waters from the pharmaceutical industries.

Ecosol is not only made available in India but for markets of Brazil, Chile, China, Indonesia and Saudi Arabia.

The technology not only reduces pollution but also saves around 25 per cent of a pharma company's current trestle water treatment cost. Further, the technology is a consumable, and can be easily incorporated into the waste water treatment process of any pharmaceutical industry, provided it does not contain fluorides and other heavy metals which impede the enzyme action, Subramani Ramachandrappa, founder and CEO, Richcore Lifesciences told Pharmabiz.

The company has also invested in a Greenfield cGMP compliant enzyme manufacturing facility to produce high value low volume enzymes used in bio pharmaceutical manufacturing and other bio transformation processes. "We provide solutions which address a definite need in the industry and our potential market is in the order of US\$ 7 to 8 billion dollars per annum. However, the real challenge we face is in creating awareness and ensuring that our technology reaches every nook and corner of the world, he added.

The company's clean technology solutions have several global applications and is also protected by several worldwide patents. "We have so far filed two patents in waste water management, 1 patent in manufacturing process design and two patents in energy application to improve ethanol production efficiency. The current product portfolio has a total market potential of over US\$ 10 billion, he said.

The company's channel partners are spread across all the continents, in 12 countries, from Japan in the east to Chile in the west.

The need of the hour is access green solutions which save costs. We have developed biotech solutions for conventional industries that does not require capital expenditure but provides cost saving enzyme solutions to conserve food, water and energy. Our novel solutions are patented, validated and tested in several countries. We have ensured that the solutions we provide do not cannibalize any existing technology but works synergistically creating real value to the end user industry, said Ramachandrappa, who is an alumni of Indian School of Business, Hyderabad.

There are very few players developing solutions similar to those of Richcore. On the competition from global markets, he said that the target markets are huge and will attract more competition in the coming years. Richcore currently enjoys a little safety with its patents and first mover advantage in developing traction for its novel applications, he said.